Overview

Aprepitant is a neurokinin-1 (NK1, or substance P) receptor antagonist used together with a 5-HT3 antagonist and dexamethasone to prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV). In the injectable form, it is supplied as a ready-to-use emulsion in a single-dose vial, given as a one-time Day 1 infusion before highly or moderately emetogenic chemotherapy. For procurement teams, the relevant concerns are sterility, cold-chain discipline, and uninterrupted supply for oncology units that rely on it every treatment cycle.

The biological rationale is well established: substance P, acting through NK1 receptors in the brainstem vomiting center, mediates the delayed nausea that older antiemetic regimens often missed. Blocking this pathway is why the NK1 antagonist became a standard third pillar of antiemetic prophylaxis alongside serotonin blockade and corticosteroids, and why it is planned into the regimen before chemotherapy begins.

Why the IV Form Matters

Oral aprepitant requires patients to swallow capsules on a three-day schedule, which is not always practical for those who are nauseated or fasting before infusion. The intravenous emulsion consolidates the NK1 blockade into a single pre-chemotherapy dose, simplifying the antiemetic regimen. This convenience translates into operational value: fewer administration steps and a predictable, standardized pre-medication order set.

Cold-Chain and Storage Discipline

As a sterile injectable emulsion, aprepitant vials must be stored and transported according to the manufacturer's labeled conditions, typically protected from freezing and excessive heat, and inspected before use. Buyers should confirm that suppliers maintain validated cold-chain monitoring and that receiving pharmacies have a clear put-away and expiry-rotation process. A broken cold chain can compromise a product that cannot be visually verified as defective.

Supplier Qualification

Because antiemetics are scheduled around fixed chemotherapy days, stockouts directly disrupt patient care. Qualifying a supplier means reviewing manufacturing licenses, batch release documentation, and a track record of on-time delivery. Institutions often keep a primary and backup source to protect continuity during demand spikes or regional shortages.

FAQ

Q: How is aprepitant IV emulsion dosed for CINV? A: It is typically given as a single intravenous dose on Day 1 of chemotherapy, combined with a 5-HT3 antagonist and dexamethasone per local protocols.

Q: What should procurement verify before purchase? A: Confirm GMP manufacturing, cold-chain handling, batch documentation, and the supplier's delivery reliability for time-sensitive oncology use.

Q: Why choose the injectable over capsules? A: The emulsion provides a single-dose pre-chemotherapy option for patients who cannot easily take oral medication on a multi-day schedule.